Share

Last chance for media to register for ECCO 14 -- the European Cancer Conference

Don't miss news of best cancer research in Europe and the world

In more than 1,300 presentations from scientists working in 75 countries, the conference will discuss the latest advances in stem cell research, proteomics, biomarkers, pharmacogenomics, imaging, treatment and coping with life after cancer, as well as the latest evidence on epidemiological trends, complementary therapies, quality of life issues and the influence of lifestyle choices on the development and outcome of cancer. The programme includes more new results from phase III clinical trials than ever before.

There will be media news briefings at the following times:

• Monday 24 September (11.00 hrs) in English

• Monday 24 September (14.30 hrs) in Spanish (embargoed to Tuesday 25 September)

• Tuesday 25 September (11.00 hrs) in English

• Wednesday 26 September (11.00 hrs) in English

• Thursday 27 September (10.30 hrs) in English

Here is a sample of the new results to be announced at the conference (embargoed to time of presentation at ECCO 14):

• Discovery of gene with widespread involvement in stimulating tumour growth holds out promise for treating many common cancers

• Tumour cells circulating in blood can predict which patients are likely to have a recurrence of cancer after chemotherapy treatment

• Figures on cancer control in Europe show it works; now it is time to extend it to poorer countries

• Threat to MRI scans from European Directive – how it will affect cancer diagnosis and treatment

• Identification of molecular fingerprint for resistance to commonly used chemotherapy drug can predict response to treatment in breast cancer

• Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer

• Improved treatment for difficult childhood brainstem gliomas

• First molecular profiling of colon cancer patients accurately predicts survival

• Quality of life after endometrial cancer treatment can be significantly improved by the use of internal rather than external radiotherapy

• Survey reveals ignorance and confusion about cancer among the elderly

• Researchers discover a specific genetic mutation can double or treble a woman’s risk of ovarian cancer

• Researchers discover PET is more useful than mammography or ultrasound in detecting a tumour’s response to chemotherapy and the patient’s likelihood of survival

• Can acupuncture reduce radiotherapy-induced nausea" New findings.

• Study of 70,000 women reveals whether wine, beer or spirits are most likely to trigger the onset of breast cancer, or whether they are all as bad as each other

• post traumatic stress symptoms in adolescent children of cancer patients – do their parents realise"

• study fuels debate over whether body size and exercise influence ovarian cancer risk

• Chemotherapy drug delays progression of operable pancreatic cancer

• Married oesophageal cancer patients fare worse than their single counterparts in some aspects of quality of life

• Experimental drug shows promise in advanced kidney cancer patients whose options run out after their tumour fails to respond to the cutting edge therapy

• New findings on pregnancy and cancer survival

• Couples more likely to divorce if one partner is diagnosed with certain types of cancer

• New type of drug shows promise in tackling melanoma in innovative way. . . . and much more.

Press Office opening times:
Sunday 23 September: 09.00 – 19.00
Monday 24 – Wednesday 26 September: 08.00 – 19.00
Thursday 25 September: 08.00 – 14.00

Registration and accommodation (media only)

ECCO 14 is open to bona fide representatives of print and electronic media and healthcare media. Registration is free of charge to journalists who are in possession of a valid, recognised press card. Freelance journalists must present a commissioning letter on headed paper from a recognised news organisation or publication. Details of how to register and how to obtain accommodation can be found on the FECS website at: www.fecs.be

Journalists must register in person. Applications for media registration made via pharmaceutical, marketing or public relations companies will not be considered.

Share

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.